- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01793467
Transplantation and the Use of Raltegravir in HIV-Infected Patients
Solid Organ Transplantation and the Use of Raltegravir in HIV-Infected Patients: An Observational Study of Pharmacokinetics, Safety, Tolerability and Efficacy
Raltegravir (RAL) is a preferred option for initial antiretroviral therapy in the most recent HIV Treatment Guidelines and is emerging as a popular choice for use in the specialized population of HIV-infected patients being considered for solid organ transplantation. Data from HIV-infected persons with normal organ function have revealed few raltegravir-associated metabolic complications compared to older antiretrovirals, and in general, drug-drug interactions with raltegravir are infrequent. The absence of such concerns appears to make raltegravir a potentially appealing option for antiretroviral therapy in HIV-infected patients being considered for solid organ transplantation.
At present, however, little is known of the safety and long term tolerability of RAL-containing regimens in persons undergoing solid organ transplantation. As more HIV-infected patients undergo organ transplantation, there is a growing need for good data on such things as the effect of dialysis on RAL concentrations, the potential interactions with commonly used immunosuppressive drugs, and the pharmacokinetic (PK) /pharmacodynamic (PD) characteristics in those with end stage organ failure, as well as those with functioning grafts.
The proposed study will also examine transplant function and survival in HIV-infected patients receiving RAL-containing ART and will compare it to HIV negative historic controls.
Study Overview
Status
Detailed Description
Pre-transplant:
- Patients on stable antiretroviral regimens who undergo evaluation for transplantation and are subsequently placed on the transplant waiting list will be considered for inclusion in the study. The details of the cART for each patient will remain the sole purview of the patient and the patient's HIV care provider.
To be considered for solid organ transplantation, in addition to routine transplant listing criteria, the patient must fulfill the following criteria:
- non-pregnant adult patient with CD4 count >200/μL;
- no concurrent active AIDS-defining infections or malignancy;
- at least 24 months of well controlled HIV viremia, defined as <50 copies for the majority of the time.
After all screening procedures have been completed to ensure eligibility, a pre-transplant pharmacokinetic study will be done as described below. Using specimens obtained during 7 time points, patient-specific Cmax, Cmin and AUC determinations will be made using standard calculation approaches. The PK data will also include samples drawn on dialysis days for patients with End-stage renal failure:- pre-dialysis, arterial and venous concentrations (Cin and Cout) at the beginning of dialysis, and post dialysis levels (to determine individual hemodialysis extraction ratios).
Additional data to be collected include a Quality of Life questionnaire, SF-36, and a PHQ-9 depression screen which will be administered as a baseline test done at enrollment. Patients will be asked to have a dual-emission X-ray absorptiometry (DEXA) scan prior to transplant (unless this has been completed within two years of enrollment).
Peri-transplant Assessments:
In addition to the standard of care laboratory and imaging procedures that are done around the time of organ transplantation, the following research samples will be collected:
- Pre-transplant - RAL concentrations
- In addition, the following information will be recorded from the subject's medical record: full HIV and infective history and test results including CD4 count, and percentage, HIV viral load, electrocardiography (to assess QTc interval), CMV-IgG/IgM, Hepatitis B, C, D screens +/- viral loads if not already determined.
Post-transplant inpatient hospitalization
- RAL concentrations as well as HIV viral load and CD4/CD8 lymphocyte populations.
- In addition, the following information will be recorded from the subject's medical record: test results including EKG (to assess QTc interval).
Post-transplant:
- RAL concentrations will be collected at Months 1 and 3 only.
- In addition to the routine post-transplant care, the following information will be collected from the subject's medical records at study months 1, 3, 6, 9, 12, 24 post transplant: CD4 count and %, HIV viral load (+/- genotype and integrase mutation analysis if viral rebound occurs), Vitamin D, Basic Metabolic Panel (to calculate ClCr), quantitative urinary creatinine and protein excretion. Patient side-effect card will be ascertained by directed questioning from the study coordinator at each visit.
Repeat DEXA scan will be done at the 24 months post-transplant visit. Quality of Life assessment and depression screening tools will be administered at the 6 and 24 month marks.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 277138270
- Duke University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- non-pregnant adult patient with CD4 count >200/μL
- no concurrent active AIDS-defining infections or malignancy
- at least 24 months of well controlled HIV viremia, defined as <50 copies for the majority of the time.
- otherwise suitable transplant candidates, actively listed
- currently taking Raltegravir for control of HIV infection
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To examine raltegravir (RAL) in the management of HIV-infected persons listed for solid organ transplantation, with a focus on mortality and graft survival
Time Frame: 3+ years
|
3+ years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess Raltegravir viability as a long term HIV treatment drug for patients undergoing transplant
Time Frame: 3+ years
|
a) Measure RAL PK in HIV-infected patients with end-stage renal failure (ESRF), who are receiving dialysis pre-transplant. b) Assess raltegravir PK in patients with different severities of liver disease, including cirrhosis, when such patients are available. d) Assess the ability of RAL-centered ART combinations to maintain HIV suppression and CD4 counts following solid-organ transplant. |
3+ years
|
determine the viability of grafted organs in patients with HIV infections
Time Frame: 3+ years
|
|
3+ years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Cameron R Wolfe, MD, Duke University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00036598
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Positive
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
Therapeutic ConceptsJanssen Scientific Affairs, LLCUnknown
-
University of WashingtonSeattle Children's Hospital; University of NairobiCompleted
-
Universidad Autónoma del Estado de HidalgoNational Council of Science and Technology, MexicoCompleted
-
Bayside HealthMerck Sharp & Dohme LLCUnknown
-
Holdsworth House Medical PracticeCompleted
-
Absolute Return for KidsUnited States Agency for International Development (USAID); Department for... and other collaboratorsCompleted